NASDAQ:KPRX Kiora Pharmaceuticals (KPRX) Stock Price, News & Analysis $3.20 0.00 (0.00%) Closing price 04/25/2025 03:58 PM EasternExtended Trading$3.24 +0.04 (+1.41%) As of 04/25/2025 06:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Kiora Pharmaceuticals Stock (NASDAQ:KPRX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Kiora Pharmaceuticals alerts:Sign Up Key Stats Today's Range$3.17▼$3.2350-Day Range$2.59▼$3.5152-Week Range$2.51▼$5.55Volume9,261 shsAverage Volume31,173 shsMarket Capitalization$9.60 millionP/E Ratio3.08Dividend YieldN/APrice Target$10.00Consensus RatingStrong Buy Company OverviewKiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, and KIO-104 for the treatment of posterior non-infectious uveitis; and KIO-201, an eye drop, which is in Phase 3b clinical trial for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.Read More… Kiora Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks83rd Percentile Overall ScoreKPRX MarketRank™: Kiora Pharmaceuticals scored higher than 83% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingStrong Buy Consensus RatingKiora Pharmaceuticals has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageKiora Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Kiora Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Kiora Pharmaceuticals are expected to decrease in the coming year, from $1.28 to ($2.76) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kiora Pharmaceuticals is 3.08, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 21.70.Price to Earnings Ratio vs. SectorThe P/E ratio of Kiora Pharmaceuticals is 3.08, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 22.43.Price to Book Value per Share RatioKiora Pharmaceuticals has a P/B Ratio of 0.45. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Kiora Pharmaceuticals' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.16% of the float of Kiora Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverKiora Pharmaceuticals has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Kiora Pharmaceuticals has recently decreased by 10.08%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldKiora Pharmaceuticals does not currently pay a dividend.Dividend GrowthKiora Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.16% of the float of Kiora Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverKiora Pharmaceuticals has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Kiora Pharmaceuticals has recently decreased by 10.08%, indicating that investor sentiment is improving significantly. News and Social Media4.4 / 5News SentimentN/A News SentimentKiora Pharmaceuticals has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.86 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Kiora Pharmaceuticals this week, compared to 0 articles on an average week.Search Interest1 people have searched for KPRX on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Kiora Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Kiora Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.94% of the stock of Kiora Pharmaceuticals is held by insiders.Percentage Held by Institutions76.97% of the stock of Kiora Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Kiora Pharmaceuticals' insider trading history. Receive KPRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kiora Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address KPRX Stock News HeadlinesKiora Pharmaceuticals Advances Retinal Disease PipelineMarch 26, 2025 | tipranks.comKiora Pharmaceuticals secures new patent for KIO-104February 13, 2025 | msn.com$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being carried out by the Fed that has nothing to do with lowering or raising interest rates... but could soon have an enormous impact on your wealth.April 27, 2025 | Stansberry Research (Ad)We Think Kiora Pharmaceuticals' (NASDAQ:KPRX) Healthy Earnings Might Be ConservativeNovember 15, 2024 | finance.yahoo.comKiora Pharmaceuticals’ Promising Growth Prospects: Buy Rating Backed by Clinical Advancements and Strong Financial PositionNovember 13, 2024 | markets.businessinsider.comPositive Developments and Strategic Partnerships Propel Kiora Pharmaceuticals to a Buy RatingNovember 1, 2024 | markets.businessinsider.comKiora Pharmaceuticals Gains Approval for Phase 2 TrialOctober 29, 2024 | markets.businessinsider.comKiora Pharmaceuticals (NASDAQ:KPRX) Stock Quotes, Forecast and News SummaryOctober 5, 2024 | benzinga.comSee More Headlines KPRX Stock Analysis - Frequently Asked Questions How have KPRX shares performed this year? Kiora Pharmaceuticals' stock was trading at $3.30 on January 1st, 2025. Since then, KPRX stock has decreased by 3.0% and is now trading at $3.20. View the best growth stocks for 2025 here. How were Kiora Pharmaceuticals' earnings last quarter? Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) released its quarterly earnings results on Tuesday, March, 25th. The company reported ($1.04) earnings per share for the quarter, missing the consensus estimate of ($0.64) by $0.40. The business had revenue of $0.75 million for the quarter, compared to analysts' expectations of $0.75 million. When did Kiora Pharmaceuticals' stock split? Kiora Pharmaceuticals shares reverse split before market open on Tuesday, June 11th 2024. The 1-9 reverse split was announced on Tuesday, June 11th 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, June 11th 2024. An investor that had 100 shares of stock prior to the reverse split would have 11 shares after the split. How do I buy shares of Kiora Pharmaceuticals? Shares of KPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Kiora Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Kiora Pharmaceuticals investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), Jabil (JBL) and CrowdStrike (CRWD). Company Calendar Last Earnings3/25/2025Today4/27/2025Next Earnings (Estimated)5/09/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:KPRX CIK1372514 Webeyegatepharma.com Phone(781) 788-9043FaxN/AEmployees10Year FoundedN/APrice Target and Rating Average Stock Price Target$10.00 High Stock Price Target$10.00 Low Stock Price Target$10.00 Potential Upside/Downside+212.5%Consensus RatingStrong Buy Rating Score (0-4)3.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)$1.04 Trailing P/E Ratio3.08 Forward P/E Ratio2.50 P/E GrowthN/ANet Income$-12,510,000.00 Net MarginsN/A Pretax Margin35.21% Return on Equity21.32% Return on Assets16.39% Debt Debt-to-Equity RatioN/A Current Ratio8.97 Quick Ratio8.97 Sales & Book Value Annual Sales$16 million Price / Sales0.60 Cash FlowN/A Price / Cash FlowN/A Book Value$7.14 per share Price / Book0.45Miscellaneous Outstanding Shares3,001,000Free Float2,973,000Market Cap$9.60 million OptionableNot Optionable Beta-0.53 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free Report This page (NASDAQ:KPRX) was last updated on 4/27/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump’s tariffs just split the AI market in twoTrump’s tariff just split the AI market – among others – in two. One group of AI companies—the ones relying...Traders Agency | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredTrump purposefully forcing markets to crash…Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you re...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kiora Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kiora Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.